ETF Financing Ranking | GF CSI HK Innovative Drugs Industry ETF(QDII) (513120) had a net financing buy-in of CNY 37.51 million, ranked in the first tier of the entire market-20260608

Jun 8, 2026, GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.SH) decreased by 3.71%, had a turnover of CNY 3.17 billion. Obtained financing buy-in of CNY 279.55 million, and financing repayment of CNY 242.04 million, with a net financing buy-in of CNY 37.51 million, ranked in the first tier of the entire market. (Data source: Wind)

Over a longer period, had leveraged funds with continuous inflow over the last 2 days, with a total inflow of CNY 102.83 million, ranked in the first tier of the entire market. (Data source: Wind)

GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.SH), off-exchange connection (A type: 019670; C type: 019671).

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.